Does the media refer more to GPCR or COLL?

In the previous week, Collegium Pharmaceutical had 7 more articles in the media than Structure Therapeutics. MarketBeat recorded 11 mentions for Collegium Pharmaceutical and 4 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.32 beat Collegium Pharmaceutical's score of 1.02 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Collegium Pharmaceutical 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor COLL or MBX?

In the previous week, Collegium Pharmaceutical had 4 more articles in the media than MBX Biosciences. MarketBeat recorded 11 mentions for Collegium Pharmaceutical and 7 mentions for MBX Biosciences. Collegium Pharmaceutical's average media sentiment score of 1.02 beat MBX Biosciences' score of 1.01 indicating that Collegium Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive MBX Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer COLL or TARS?

In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 14 mentions for Tarsus Pharmaceuticals and 11 mentions for Collegium Pharmaceutical. Tarsus Pharmaceuticals' average media sentiment score of 1.63 beat Collegium Pharmaceutical's score of 1.02 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Collegium Pharmaceutical (COLL) Competitors

$25.35 -1.09 (-4.12%)

As of 08/28/2026 04:00 PM Eastern

Compare

COLL vs. GPCR, MBX, TARS, ARQT, and MOR

Should you buy Collegium Pharmaceutical stock or one of its competitors? Collegium Pharmaceutical's main competitors and comparable companies include Structure Therapeutics (GPCR), MBX Biosciences (MBX), Tarsus Pharmaceuticals (TARS), Arcutis Biotherapeutics (ARQT), and MorphoSys (MOR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Collegium Pharmaceutical compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Collegium Pharmaceutical (NASDAQ:COLL) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Structure Therapeutics presently has a consensus target price of $110.91, indicating a potential upside of 134.13%. Collegium Pharmaceutical has a consensus target price of $51.00, indicating a potential upside of 101.18%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Collegium Pharmaceutical	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71

91.8% of Structure Therapeutics shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Collegium Pharmaceutical had 7 more articles in the media than Structure Therapeutics. MarketBeat recorded 11 mentions for Collegium Pharmaceutical and 4 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.32 beat Collegium Pharmaceutical's score of 1.02 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Collegium Pharmaceutical has a net margin of 5.93% compared to Structure Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 91.43% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-25.56%	-24.31%
Collegium Pharmaceutical	5.93%	91.43%	15.57%

Structure Therapeutics has a beta of -1.43, indicating that its stock price is 243% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

Collegium Pharmaceutical has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A
Collegium Pharmaceutical	$808.21M	1.02	$62.87M	$1.24	20.44

Summary

Collegium Pharmaceutical beats Structure Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to MBX Biosciences?

Collegium Pharmaceutical (NASDAQ:COLL) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

Collegium Pharmaceutical has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

Collegium Pharmaceutical has a net margin of 5.93% compared to MBX Biosciences' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 91.43% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	5.93%	91.43%	15.57%
MBX Biosciences	N/A	-26.02%	-24.94%

Collegium Pharmaceutical presently has a consensus price target of $51.00, suggesting a potential upside of 101.18%. MBX Biosciences has a consensus price target of $77.00, suggesting a potential upside of 22.22%. Given Collegium Pharmaceutical's higher possible upside, equities research analysts clearly believe Collegium Pharmaceutical is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

Collegium Pharmaceutical has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$808.21M	1.02	$62.87M	$1.24	20.44
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

In the previous week, Collegium Pharmaceutical had 4 more articles in the media than MBX Biosciences. MarketBeat recorded 11 mentions for Collegium Pharmaceutical and 7 mentions for MBX Biosciences. Collegium Pharmaceutical's average media sentiment score of 1.02 beat MBX Biosciences' score of 1.01 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
MBX Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Collegium Pharmaceutical beats MBX Biosciences on 11 of the 13 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Tarsus Pharmaceuticals?

Collegium Pharmaceutical (NASDAQ:COLL) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 14 mentions for Tarsus Pharmaceuticals and 11 mentions for Collegium Pharmaceutical. Tarsus Pharmaceuticals' average media sentiment score of 1.63 beat Collegium Pharmaceutical's score of 1.02 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	12 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Collegium Pharmaceutical has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$808.21M	1.02	$62.87M	$1.24	20.44
Tarsus Pharmaceuticals	$451.36M	6.98	-$66.42M	-$1.09	N/A

Collegium Pharmaceutical currently has a consensus target price of $51.00, indicating a potential upside of 101.18%. Tarsus Pharmaceuticals has a consensus target price of $90.50, indicating a potential upside of 26.11%. Given Collegium Pharmaceutical's higher possible upside, research analysts plainly believe Collegium Pharmaceutical is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Collegium Pharmaceutical has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

Collegium Pharmaceutical has a net margin of 5.93% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Collegium Pharmaceutical's return on equity of 91.43% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	5.93%	91.43%	15.57%
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Collegium Pharmaceutical beats Tarsus Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Collegium Pharmaceutical (NASDAQ:COLL) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Arcutis Biotherapeutics currently has a consensus price target of $35.57, indicating a potential upside of 49.59%. Collegium Pharmaceutical has a consensus price target of $51.00, indicating a potential upside of 101.18%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe Collegium Pharmaceutical is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Collegium Pharmaceutical	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 15 mentions for Arcutis Biotherapeutics and 11 mentions for Collegium Pharmaceutical. Arcutis Biotherapeutics' average media sentiment score of 1.15 beat Collegium Pharmaceutical's score of 1.02 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	11 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

Collegium Pharmaceutical has higher revenue and earnings than Arcutis Biotherapeutics. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$463.98M	6.44	-$16.14M	$0.21	113.24
Collegium Pharmaceutical	$808.21M	1.02	$62.87M	$1.24	20.44

Arcutis Biotherapeutics has a net margin of 6.15% compared to Collegium Pharmaceutical's net margin of 5.93%. Collegium Pharmaceutical's return on equity of 91.43% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Collegium Pharmaceutical	5.93%	91.43%	15.57%

Summary

Collegium Pharmaceutical beats Arcutis Biotherapeutics on 8 of the 15 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to MorphoSys?

Collegium Pharmaceutical (NASDAQ:COLL) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Collegium Pharmaceutical has a net margin of 5.93% compared to MorphoSys' net margin of -226.79%. Collegium Pharmaceutical's return on equity of 91.43% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	5.93%	91.43%	15.57%
MorphoSys	-226.79%	-694.31%	-22.55%

Collegium Pharmaceutical currently has a consensus target price of $51.00, suggesting a potential upside of 101.18%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, equities research analysts plainly believe Collegium Pharmaceutical is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Collegium Pharmaceutical has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$808.21M	1.02	$62.87M	$1.24	20.44
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

In the previous week, Collegium Pharmaceutical had 11 more articles in the media than MorphoSys. MarketBeat recorded 11 mentions for Collegium Pharmaceutical and 0 mentions for MorphoSys. Collegium Pharmaceutical's average media sentiment score of 1.02 beat MorphoSys' score of 0.00 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Overall Sentiment
Collegium Pharmaceutical	Positive
MorphoSys	Neutral

Collegium Pharmaceutical has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

18.4% of MorphoSys shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Collegium Pharmaceutical beats MorphoSys on 14 of the 17 factors compared between the two stocks.

Get Collegium Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COLL vs. The Competition

Export

Metric	Collegium Pharmaceutical	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$825.29M	$12.15B	$7.20B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	20.44	787.65	273.16	25.45
Price / Sales	1.02	792.41	592.59	73.08
Price / Cash	1.67	91.95	76.74	53.00
Price / Book	2.65	11.97	12.98	6.14
Net Income	$62.87M	$2.83B	$3.48B	$348.86M
7 Day Performance	-6.49%	0.39%	0.13%	-0.80%
1 Month Performance	-29.54%	5.34%	7.08%	4.13%
1 Year Performance	-34.66%	6.05%	24.67%	15.17%

Collegium Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COLL Collegium Pharmaceutical	2.8324 of 5 stars	$25.35 -4.1%	$51.00 +101.2%	-34.7%	$825.29M	$808.21M	20.44	210	News Coverage Positive News
GPCR Structure Therapeutics	2.2036 of 5 stars	$49.01 -0.2%	$110.91 +126.3%	+145.4%	$3.42B	N/A	N/A	136	Positive News
MBX MBX Biosciences	2.517 of 5 stars	$66.39 +0.1%	$77.00 +16.0%	+317.5%	$3.19B	N/A	N/A	N/A	News Coverage
TARS Tarsus Pharmaceuticals	3.7513 of 5 stars	$72.81 +0.2%	$90.50 +24.3%	+22.5%	$3.19B	$451.36M	N/A	50	News Coverage Positive News
ARQT Arcutis Biotherapeutics	4.1278 of 5 stars	$24.78 -1.2%	$35.57 +43.5%	+53.2%	$3.15B	$376.07M	118.01	150	News Coverage Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COLL) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Collegium Pharmaceutical (COLL) Competitors

COLL vs. GPCR, MBX, TARS, ARQT, and MOR

How does Collegium Pharmaceutical compare to Structure Therapeutics?

Summary

How does Collegium Pharmaceutical compare to MBX Biosciences?

Summary

How does Collegium Pharmaceutical compare to Tarsus Pharmaceuticals?

Summary

How does Collegium Pharmaceutical compare to Arcutis Biotherapeutics?

Summary

How does Collegium Pharmaceutical compare to MorphoSys?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COLL vs. The Competition

Collegium Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Collegium Pharmaceutical (COLL) Competitors

COLL vs. GPCR, MBX, TARS, ARQT, and MOR

How does Collegium Pharmaceutical compare to Structure Therapeutics?

Do analysts rate GPCR or COLL?

Do institutionals & insiders believe in GPCR or COLL?

Does the media refer more to GPCR or COLL?

Is GPCR or COLL more profitable?

Which has more risk & volatility, GPCR or COLL?

Which has stronger valuation and earnings, GPCR or COLL?

Summary

How does Collegium Pharmaceutical compare to MBX Biosciences?

Which has more volatility and risk, COLL or MBX?

Is COLL or MBX more profitable?

Do analysts rate COLL or MBX?

Which has stronger earnings and valuation, COLL or MBX?

Does the media favor COLL or MBX?

Summary

How does Collegium Pharmaceutical compare to Tarsus Pharmaceuticals?

Does the media prefer COLL or TARS?

Which has preferable valuation and earnings, COLL or TARS?

Do analysts prefer COLL or TARS?

Which has more volatility and risk, COLL or TARS?

Is COLL or TARS more profitable?

Do insiders & institutionals hold more shares of COLL or TARS?

Summary

How does Collegium Pharmaceutical compare to Arcutis Biotherapeutics?

Do analysts recommend ARQT or COLL?

Does the media refer more to ARQT or COLL?

Which has more risk and volatility, ARQT or COLL?

Which has preferable valuation & earnings, ARQT or COLL?

Is ARQT or COLL more profitable?

Summary

How does Collegium Pharmaceutical compare to MorphoSys?

Is COLL or MOR more profitable?

Do analysts recommend COLL or MOR?

Which has preferable earnings and valuation, COLL or MOR?

Does the media refer more to COLL or MOR?

Which has more risk & volatility, COLL or MOR?

Do insiders & institutionals have more ownership in COLL or MOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COLL vs. The Competition

Collegium Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools